ECP 2024, the largest worldwide conference in pathology, brought together diverse experts and innovation drivers to share insights into the field of pathology and its contribution to modern diagnostics and precision medicine.
Thank you for joining us at the Fortezza da Basso during ECP 2024 for an engaging schedule of events and networking. We appreciated your participation as we shared how we are advancing science and breaking down barriers to elevate the practice of pathology and foster improved medical decision-making that has the power to transform lives.
Our immersive booth was a fantastic opportunity to meet our colleagues and explore how Roche is innovating and collaborating to drive diagnostic certainty for life-changing decisions across many cancers. We were excited to discuss the value of Roche high medical value solutions across the pathology and molecular work areas in helping pathologists confidently deliver the answers clinicians rely on to provide the highest standard of care.
We also hosted engaging in-person events where key opinion leaders shared and discussed their experiences and perspectives in precision diagnostics. Gain access to the recordings of these in-booth talks by registering now, and explore further details about the topics covered in our sessions below.
European Congress of Pathology (ECP)
36th European Congress of Pathology (ECP) 2024
7 - 11 September 2024
Florence, Italy
Symposia
9 September 2024
Roche Symposium
Improving the diagnosis of B-cell lymphomas in routine pathology practice: Advances in clonality evaluation
B-cell lymphomas can represent a diagnostic challenge due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations, and traditional methods of determining clonality are limited by sub-optimal sensitivity and/or cumbersome workflows. The ultra-sensitive VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay for light chain restriction will be discussed, with descriptive cases illustrating its utility.
Dr Teresa Marafioti, Professor, University College London
Dr Marta Canamero, Medical Affairs Lead, Roche Diagnostics
Moderator: Bowdoin Su, Medical Affairs Lead, Roche Diagnostics
9 September 2024
Roche and Johnson & Johnson
Joint Symposium
Pathways to precision: Practical strategies for optimising diagnostic excellence
In this precision pathology symposium we delve into key challenges and opportunities within the biomarker testing pathway. Leading pathologists will unveil innovative solutions they've successfully implemented in their laboratories, enhancing both diagnostic precision and operational efficiency. Through interactive sessions including roundtable discussions and best practice sharing, attendees will gain invaluable insights to inspire advancements in their own practice.
Introduction: Testing pathway and patient leakage points
Pr Angelo Dei Tos, Professor of Pathology at Padua University Hospital (AOUP), Italy
Increasing identification of patients with actionable target
Pr Deniz Nart, Professor of Pathology at Ege University (EU) Hospital, Turkey
Optimising the workflow to reduce failure rates
Pr Sylvie Lantuejoul, Centre Léon Bérard, France
Implementation of one NGS flow to reduce turnaround time
Pr Isabelle Vanden Bempt, Clinical Biologist at UZ Leuven, Belgium
Pr Angelo Dei Tos will chair the session
10 September 2024
Roche Symposium
Precision diagnostics in ovarian cancer: Traversing from testing to treatment
This session will highlight the history and current landscape of biomarker testing in ovarian cancer (OC) and how these markers have transformed therapy options for ovarian cancer patients. The session will highlight the newest biomarker, folate receptor alpha (FRɑ), and how identifying patients eligible for FRɑ-targeted therapy using the FDA approved VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay has shaped the treatment landscape for patients with platinum-resistant OC. The session will feature oncologist and pathologist panel speakers to give their perspectives on the ovarian cancer patient journey and incorporation of IHC FRɑ testing in this disease and will conclude with a discussion around best practices for implementing FRɑ testing for OC patients in EU countries and key considerations for both pathologists and oncologists.
Dr Michelle Shiller, Medical Director Cancer Genetics, Baylor Sammons Cancer Center and National Medical Director, Genomics and Molecular Pathology Services, PathGroup, US
Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology, Humanitas University and Director, Medical Gynaecology Oncology Unit, Humanitas San Pio X Hospital, Italy
Dr Megan Dumas, Global Medical Affairs Lead, Roche Diagnostics, will chair the session
In-booth talks
Could not join us in Florence?
Whether you didn’t make it to ECP 2024 or just missed one of our in-person events, you can still check out all of our great content focused on the critical role of diagnostic testing in precision medicine. Sign up to access our virtual event webpage, where you can access recordings of each of our ECP 2024 symposia and in-booth talks.
Sign up here to receive updates and exclusive content access
Complete this form to catch up on all the content Roche delivered at ECP 2024!
By signing up, you will gain access to our virtual event webpage, where you can explore recordings of our symposia and in-booth talks.
Related information
Reference:
- cobas HIV-1/HIV-2, Qualitative nucleic acid test for use on the cobas 5800/6800/8800 Systems US-IVD Method Sheet 09198695001-05EN